**Öffentlicher Titel**
Optimale Therapiedauer von Bevacizumab, Paclitaxel und Carboplatin bei Ovarialkarzinom

**Wissenschaftl. Titel**
Eine prospektive randomisierte Phase III Studie zur Evaluierung der optimalen Therapiedauer von Bevacizumab in Kombination mit Paclitaxel und Carboplatin bei Patientinnen mit primärem epithelialem Ovarial-, Tuben- oder Peritonealkarzinom

**Kurztitel**
AGO-OVAR-17 (Boost)

**Studienart**
multizentrisch, prospektiv, randomisiert, offen/unverblindet, Pharma-Studie, zweiarmig

**Studienphase**
Phase III

**Erkrankung**
Geschlechtsorgane: Krebserkrankungen der weiblichen Geschlechtsorgane: Eierstöcken (Ovarialkarzinom) - adjuvant

**Einschlusskriterien**
- Signed written informed consent obtained prior to initiation of any study specific procedures and treatment as confirmation of the patients awareness and willingness to comply with the study requirements
- Primary diagnosis is confirmed by specialized pathology review (Germany only)
- Females aged >= 18 years
- Histologically confirmed, newly diagnosed: 1. Epithelial ovarian carcinoma 2. Fallopian tube carcinoma 3. Primary peritoneal carcinoma AND FIGO stage IIb - IV (all grades and all histological types)
- Patients should have already undergone surgical debulking, by a surgeon experienced in the management of ovarian cancer, with the aim of maximal surgical cytoreduction according to the GCIG Conference Consensus Statement. There must be no planned surgical debulking prior to disease progression. Patients with stage III and IV disease in whom initial surgical debulking was not appropriate or possible will still be eligible providing:
  - 1. the patient has a histological diagnosis and 2. debulking surgery prior to disease progression is not foreseen
  - Patients must be able to commence cytotoxic chemotherapy within 8 weeks of cytoreductive surgery. The first dose of bevacizumab can be omitted in both arms if the investigator decides to start chemotherapy within 4 weeks of surgery
- ECOG 0-2
- Life expectancy > 3 months
- Adequate bone marrow function (within 14 days prior to randomization): 1. ANC >= 1.5 x 10^9/L 2. PLT >= 100 x 10^9/L 3. Hb >= 9 g/dL (can be post-transfusion)
- Adequate coagulation parameters (within 14 days prior to randomization): 1. Patients not receiving anticoagulant medication who have an INR <= 1.5 and an aPTT <= 1.5 x ULN 2. The use of full-dose oral or par-ental anticoagulants is permitted as long as the INR or aPTT is within therapeutic limits (according to institution medical standard) and the patient has been on a stable dose of anticoagulants for at least two weeks at the time of randomization
- Adequate liver function (within 14 days prior to randomization): 1. Serum bilirubin <= 1.5 x ULN 2. Serum transaminases <= 2.5 x ULN
- Urine dipstick for proteinuria < 2+. If urine dipstick is >= 2+, 24 hour urine must demonstrate <= 1 g of protein in 24 hours
- Adequate postoperative GFR > 40 ml/min (estimates based on the Cockroft-Gault or Jelliffe formula are sufficient)

**Ausschlusskriterien**
- Non-epithelial origin of the ovary, the fallopian tube or the peritoneum
- Borderline tumours (tumours of low malignant potential) and FIGO stage Ia - Ila tumours
- Planned intraperitoneal cytotoxic chemotherapy

© Clinical Trial Center Network (CTCN) Zentrale am Universitätsklinikum Frankfurt
Ohne Gewähr für Richtigkeit oder Vollständigkeit
Stand: 30.10.2020; Seite 1 von 3
Prior systemic anti-cancer therapy for ovarian cancer (for example chemotherapy, monoclonal antibody therapy, tyrosine kinase inhibitor therapy or hormonal therapy)

Surgery (including open biopsy) within 4 weeks prior to anticipated first dose of bevacizumab (allowing for the fact that bevacizumab can be omitted from the first cycle of chemotherapy). It is strongly recommended that an interval of 7 days is left between the insertion of any central venous access devices (CVADs) and the onset of bevacizumab treatment

Any planned surgery during the study treatment period plus 4 additional weeks to allow for bevacizumab clearance

Uncontrolled hypertension (sustained elevation of BP systolic > 150mmHg and/or diastolic > 100mmHg despite antihypertensive therapy)

Any previous radiotherapy to the abdomen or pelvis

Significant traumatic injury during 4 weeks preceding the potential first dose of bevacizumab

History or clinical suspicion of brain metastases or spinal cord compression. CT/MRI of the brain is mandatory (within 4 weeks prior to randomization) in case of suspected brain metastases. Spinal MRI is mandatory (within 4 weeks prior to randomization) in case of suspected spinal cord compression

History or evidence upon neurological examination of central nervous system (CNS) disease, unless adequately treated with standard medical therapy e.g. uncontrolled seizures

Previous Cerebro-Vascular Accident (CVA), Transient Ischaemic Attack (TIA) or Sub-Arachnoid Haemorrhage (SAH) within 6 months prior to randomization

Fertile woman of childbearing potential not willing to use adequate contraception (oral contraceptives, intrauterine device or barrier method of contraception in conjunction with spermicidal jelly or surgically sterile) for the study duration and at least 6 months afterwards

Pregnant or lactating women

Treatment with other investigational agents, or participation in another clinical trial testing a drug within the past 4 weeks before start of therapy concomitantly with this trial

Malignancies other than ovarian cancer within 5 years prior to randomization, except for adequately treated: 1. carcinoma in situ of the cervix 2. and/or basal cell skin cancer 3. and/or non-melanomatoous skin cancer 4. carcinoma in situ of the breast 5. and/or early endometrial carcinoma as specified below. Patients may have received previous adjuvant chemotherapy for other malignancies e.g. breast or colorectal carcinoma if diagnosed over 5 years ago with no evidence of subsequent recurrence

Patients with synchronous primary endometrial carcinoma, or a past history of primary endometrial carcinoma, are excluded unless ALL of the following criteria for describing the endometrial carcinoma are met: Disease stage FIGO stage <= IA (tumour invades less than one half of the myometrium)

Known hypersensitivity to bevacizumab and its excipients, Chinese hamster ovary cell products or other recombinant human or humanised antibodies

Non healing wound, active ulcer or bone fracture. Patients with granulating incisions healing by secondary intention with no evidence of facial dehiscence or infection are eligible but require 3 weekly wound examinations

History or evidence of thrombotic or hemorrhagic disorders within 6 months prior to randomization
- Clinically significant cardiovascular disease, including: 1. Myocardial infarction or unstable angina within 6 months of randomization 2. NYHA >= Grade 2 Congestive Heart Failure (CHF) 3. Poorly controlled cardiac arrhythmia despite medication (patients with rate-controlled atrial fibrillation are eligible) 4. Grade >= 3 peripheral vascular disease (i.e. symptomatic and interfering with activities of daily living requiring repair or revision)
- Current or recent (within 10 days prior to randomization) chronic use of aspirin > 325 mg/day
- Pre-existing sensory or motor neuropathy >= Grade 2
- Evidence of any other disease, metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contra-indicates the use of an investigational drug or puts the patient at high risk for treatment-related complications

<table>
<thead>
<tr>
<th>Alter</th>
<th>18 Jahre und älter</th>
</tr>
</thead>
<tbody>
<tr>
<td>Status</td>
<td>Nachbeobachtung</td>
</tr>
<tr>
<td>Fallzahl</td>
<td>800</td>
</tr>
</tbody>
</table>

**Prüfzentren**

Universitätsklinikum Frankfurt  
Medizinische Klinik II, Hämatologie/Onkologie  
Theodor-Stern-Kai 7  
60590 Frankfurt am Main  
Birgit Wilde  
Tel: 069 6301-86708  
Fax: 069 6301-83655  
birgit.wilde@kgu.de

**Sponsor**
Roche Pharma AG

**Förderer**
Roche Pharma AG

**Registrierung in anderen Studienregistern**
ClinicalTrials.gov NCT01462890  
EudraCT 2011-001015-32